Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?

Kevin Roose and Casey Newton explain why they try to include “a little chaos” when they record their New York Times tech ...

U.S. pharmaceutical company Moderna announced on June 26 (local time) that it is entering the development of an “in vivo ...

By adding legal backup to state control of Chinese private companies, Decree No. 837 affects any country receiving their ...

Congress is inching closer to deeply integrating America’s military-industrial complex with Israel’s national security state.

As black-market drugs go mainstream and legalization is within reach, entrepreneurs, investors and healthcare players are ...

There’s something quietly satisfying about the idea that a spice sitting in your kitchen cupboard could be doing double duty ...

Revvity, Inc. RVTY recently announced the expansion of artificial intelligence capabilities across its Signals software ...

Dubai's property market cooled significantly in May, with transaction values nearly halving year-on-year, but investor demand remained concentrated in off-plan developments, land acquisitions and the ...

TG Therapeutics stock is on an absolute rampage, climbing 79% in roughly the first six months of the year, as the biotech takes on Roche.

According to the authority, applicants are required to submit a recent personal photograph and a copy of a valid passport ...

Nura Bio will use the series B financing to carry two neuroprotective drug candidates through early- to mid-stage clinical studies, one targeting ALS and the other for a broader neurological profile.